Literature DB >> 8395525

Characterization of type II activin receptors. Binding, processing, and phosphorylation.

L S Mathews1, W W Vale.   

Abstract

Activins bind to two classes of cell surface proteins, type I receptors of approximately 50-55 kDa and type II receptors of approximately 70-75 kDa. The two cloned type II activin receptors belong to a new subfamily of transmembrane protein serine kinases. Antibodies directed against each of these cloned receptors were generated and used in immunoprecipitation experiments to study the properties of the type II receptors in vivo. Precipitation of affinity-labeled receptors, formed by chemical cross-linking of 125I-activin A, resulted in coprecipitation of type I receptor complexes; denaturation of the lysates prior to interaction with the antibodies resulted in precipitation of only type II receptors. Treatment of both affinity-labeled and metabolically labeled receptors with peptide N-glycosidase F revealed the presence of N-linked carbohydrate chains. Metabolic labeling of cells with [32P]orthophosphate indicated that both type II receptors were phosphoproteins containing predominantly phosphoserine, with small amounts of phosphothreonine, but no detectable phosphotyrosine. Analysis of tryptic phosphopeptide maps of wild-type and kinase-defective mutants suggested that at least some of the phosphorylated sites arose from autophosphorylation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395525

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.

Authors:  Jonathan W Lowery; Jose M Amich; Alex Andonian; Vicki Rosen
Journal:  Cell Mol Life Sci       Date:  2013-12-15       Impact factor: 9.261

2.  Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.

Authors:  J J Lebrun; W W Vale
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  Cripto forms a complex with activin and type II activin receptors and can block activin signaling.

Authors:  Peter C Gray; Craig A Harrison; Wylie Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

4.  Activation of signalling by the activin receptor complex.

Authors:  L Attisano; J L Wrana; E Montalvo; J Massagué
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

5.  Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor.

Authors:  K Tsuchida; L S Mathews; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin.

Authors:  J Cárcamo; F M Weis; F Ventura; R Wieser; J L Wrana; L Attisano; J Massagué
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

7.  Biochemical evidence for the autophosphorylation and transphosphorylation of transforming growth factor beta receptor kinases.

Authors:  F Chen; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells.

Authors:  Deh-Ming Chang; Shao-Hsiang Liu; Herng-Sheng Lee; Jenn-Hung Lai; Chen-Hung Chen
Journal:  Rheumatol Int       Date:  2007-04-14       Impact factor: 2.631

9.  Activin betaA subunit, follistatin and follistatin-like 3 are expressed in the endometrium of ovariectomized rats and regulated by estrogen replacement.

Authors:  Márcia C Ferreira; Inês K D Cavallo; Pasquale Florio; Felice Petraglia; Fernando M Reis
Journal:  J Mol Histol       Date:  2008-09-09       Impact factor: 2.611

10.  Crystal structure of activin receptor type IIB kinase domain from human at 2.0 Angstrom resolution.

Authors:  Seungil Han; Pat Loulakis; Matt Griffor; Zhi Xie
Journal:  Protein Sci       Date:  2007-10       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.